MDxHealth Suspends Annual Outlook After Sales Turnover
The Irvine-based company reported $22.7 million in preliminary third-quarter revenue while adjusting its sales force.
Updated on Oct. 15, 2026 in Economic Indicators
Live Poll
Do you trust companies to meet their financial goals after losing key staff members?
MDxHealth announced preliminary third-quarter 2026 revenue of $22.7 million and suspended its full-year revenue guidance of $110-115 million. The company cited significant turnover within its sales force following the discontinuation of its Resolve mdx operation.
Why it matters
Unexpected turnover in the sales team led to revenue figures that fell short of internal expectations. The firm is now working to fortify its sales territories to restore consistent execution.
The company reported third-quarter tissue-based test volume at 11,232 units, an 11% decrease compared to the prior-year period. Liquid-based test volume reached 11,792 units, with cash and equivalents totaling $31.7 million as of September 30.
The players
MDxHealth
This company is a commercial-stage precision diagnostics firm headquartered in Irvine that specializes in urologic health testing.
The details
The recent discontinuation of the Resolve mdx operation triggered a wave of departures among sales staff, directly impacting the firm's ability to maintain anticipated testing volumes. Management is currently restructuring the affected sales territories to stabilize operations moving forward.
Timeline
September 30, 2026: Third quarter concludes with $31.7 million in cash holdings.
October 15, 2026: Preliminary Q3 revenue and guidance suspension announced.
November 12, 2026: Full Q3 results and earnings call scheduled.
Macro View
The suspension of the 2026 fiscal year revenue guidance marks a departure from the company's previously stated annual growth targets. This shift highlights the vulnerability of specialized diagnostic firms when internal restructuring disrupts established sales cycles.
The suspension of annual revenue guidance suggests potential volatility for investors monitoring the company's fiscal health and market stability. As management focuses on stabilizing the sales force, the immediate impact remains limited to internal operations rather than direct consumer pricing.
The takeaway
Maintaining a stable sales force is essential for firms transitioning away from legacy product lines to prevent service disruptions. Investors and stakeholders should look toward the upcoming November earnings call to understand how the company plans to restore its revenue trajectory.
What happens next
MDxHealth will release its full financial results for the third quarter and host an earnings call on November 12, 2026.
Further reading
For broader trends affecting local corporate performance, visit the Irvine Economic Indicators section.
Live Poll
Do you trust companies to meet their financial goals after losing key staff members?
